Improving Cancer Immunotherapy by Cell Membrane‐Camouflaged Nanoparticles

Ziling Zeng,Kanyi Pu

DOI: https://doi.org/10.1002/adfm.202004397

IF: 19

2020-08-07

Advanced Functional Materials

Abstract:<p>Cancer immunotherapy has received tremendous attention in the past decade owing to its clinical successes with the use of immune‐checkpoint inhibition and chimeric antigen receptor T cell therapy. However, only a small proportion of the patients have benefited from these immunotherapeutic drugs, which has raised concerns about the low response rate and immune‐related adverse events. Nanomedicines have served as a paradigm for preferential tumor accumulation but still confront issues such as poor circulation and insufficient tumor accumulation. By virtue of coating nanoparticles with cell membranes from diverse cell sources, active proteins on cell membranes can impart a variety of desired functionalities or supplementary therapeutic effects to nanoparticles, providing ways for enhanced cancer immunotherapy. In this review, the recent advances of cell membrane camouflaged nanoparticles applied to the improved immunotherapy are discussed on the basis of different sources of cell membranes and corresponding working mechanisms. These biomimetic nanoparticles can potentially deliver therapeutic agents to the designated sites and actively engage in particular stages of the cancer immunity cycle, eliciting antitumor immunity with less off‐target toxicities.</p>

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

This paper aims to solve the main problems encountered in cancer immunotherapy, specifically including:

1. **Low response rate**: Although immune - checkpoint inhibitors (ICI) and chimeric antigen receptor T - cell therapy (CAR - T) have achieved certain success clinically, only a small number of patients have a significant response to these immunotherapy drugs. This has led to concerns about the low response rate and immune - related adverse events.

2. **Delivery efficiency of nano - drugs**: Although nano - drugs have shown certain advantages as an example of tumor accumulation, they still face problems such as short circulation time and insufficient tumor accumulation. These problems limit the application effect of nano - drugs in the clinic.

3. **Immune side effects**: Current ICI treatments usually involve systemic administration of monoclonal antibodies, resulting in off - target toxicity and the occurrence of immune - related adverse events. In addition, the combined use of multiple immune - checkpoint blockers can improve the curative effect, but it also increases the risk of acute inflammatory side effects, such as hepatitis, dermatitis and colitis.

In order to solve the above problems, this paper explores methods to improve cancer immunotherapy by using cell membrane - camouflaged nanoparticles (CMCNs). CMCNs endow nanoparticles with specific functions or supplementary therapeutic effects through cell membrane coatings extracted from different cell sources, thereby improving the effect of cancer immunotherapy. These bionic nanoparticles can more effectively deliver therapeutic agents to the designated sites, actively participate in specific stages of the cancer immune cycle, stimulate anti - tumor immune responses, and at the same time reduce off - target toxicity.